Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes

Reese, Justin; Blau, Hannah; Casiraghi, E.; Bergquist, Timothy; Loomba, Johanna; Callahan, Tiffany J; Laraway, Bryan; Antonescu, Corneliu; Coleman, Benjamin; Gargano, Michael; Wilkins, Kenneth J.; Cappelletti, Luca; Fontana, Tommaso; Ammar, Nariman; Antony, Blessy; Murali, T. M.; Caufield, J. Harry; Karlebach, Guy; McMurry, Julie A.; Williams, Andrew E.; Moffitt, Richard A.; Banerjee, Jineta; Solomonides, Anthony; Davis, Hannah; Kostka, Kristin; Valentini, Giorgio; Sahner, David; Chute, Christopher G.; Madlock‐Brown, Charisse; Haendel, Melissa; Robinson, Peter N.; Spratt, Heidi; Visweswaran, Shyam; Flack, Joe E; Yoo, Yun Jae; Gabriel, Davera; Alexander, G. Caleb; Mehta, Hemalkumar B.; Liu, Feifan; Miller, Robert T.; Wong, Rachel; Hill, Elaine; Thorpe, Lorna E.; Divers, Jasmin

doi:10.1016/j.ebiom.2022.104413

Cited by 105 publications

(105 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple mechanisms are likely responsible, considering the heterogeneity of these acute and PASC phenotypes. In a recent report, Reese et al (2023) accessed electronic health records of nearly 3 million COVID-19+ patients. From this group, 5,645 had “long COVID” diagnoses.…”

Section: Sars-cov-2 and The Cnsmentioning

confidence: 99%

Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19

Frank

Fleshner

Maier

2023

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Section: Sars-cov-2 and The Cnsmentioning

confidence: 99%

Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19

Frank

Fleshner

Maier

2023

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

“…Efforts too to develop more standardized assessment and evaluation procedures are strongly indicated. 51,52 In the interim it can be assumed that a substantive proportion of older COVID-19 survivors may continue to incur post-COVID related albeit delayed and persistent adverse physical, mental and medical symptoms that reduce, rather than foster, longevity and life quality. These complaints are not merely signs of aging or emotional distress alone, and many older adults who already have multiple needs and who cannot take on a highly proactive approach to their recovery must hence warrant special attention.…”

Section: Discussionmentioning

confidence: 99%

Aging and long COVID-19 syndrome: what’s new in 2023?

Marks¹

2023

MOJGG

View full text Add to dashboard Cite

Since 2019 that saw the onset of the COVID-19 pandemic, its ongoing impact on many older adults remains a persistent public health concern, especially among those who report suffering from long or post-acute COVID-19 disease health challenges. This report presents data published largely since January 1 2023 on this topic and concerning: Long COVID or COVID-19, Older Adults, Post-Acute COVID-19 Outcomes, and Prevention. Data show that even though long COVID-19 was discussed in 2021 at some length, it still remains a relatively unchartered poorly understood topic in which a sizeable percentage of older adult COVID-19 survivors may experience delayed features of breathing, movement, cognitive and mental health challenges. What causes the observed and perceived problems, what may help to identify who is at risk, and what will reduce these remains unknown, but may benefit from insightful research and extended observations and possible.

show abstract

“…Data reporting systems should be adaptive and flexible [22] to collect and analyze follow‐up data from individuals who test positive for the virus across all age groups. Such data repositories in HICs have enabled analyses such as modeling of phenotype data [23] and risks for cardiovascular disease and mortality events [24]. Additionally, available diagnostics and technologies in HICs have led to a better understanding of cellular and molecular mechanisms of Long Covid, which will facilitate the development of effective treatments.…”

Section: Addressing Long Covid: Research Diagnosis and Treatmentmentioning

confidence: 99%

Long Covid: A call for global action

Amit

Pepito

Dayrit

2023

Public Health Challenges

View full text Add to dashboard Cite

The COVID‐19 pandemic has resulted in another global health crisis with millions of individuals with Long Covid experiencing disability, worse health‐related quality of life, and productivity and income losses. Despite its impact on population health outcomes, health systems, and the economy, there remains a need for a global consensus on its standard definition, diagnostic approaches, and treatment plans to manage symptoms. In many low‐ and middle‐income countries (LMICs), there are limited published estimates on Long Covid, limited studies on its diagnostics and therapeutics, and limited media and news coverage. We advocate for a global action plan and necessary investments on Long Covid research and treatment, meaningful involvement of patients and cooperation between high‐income countries and LMICs, stronger and more effective public health communication surrounding the risks of Long Covid, and support toward financial risk protection as advocated by Universal Health Care.

show abstract

Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes

Cited by 105 publications

References 55 publications

Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19

Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19

Aging and long COVID-19 syndrome: what’s new in 2023?

Long Covid: A call for global action

Contact Info

Product

Resources

About